Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On October 3, 2022, Imunon, Inc. (the "Company") announced that the Board of
Directors (the "Board") appointed James E. Dentzer to the Board as a Class II
Director effective September 29, 2022. Mr. Dentzer has served as the President
and Chief Executive Officer and a member of the Board of Directors of Curis,
Inc. ("Curis"), a biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, since September 2018. From March 2018
to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and
Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as
Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer
also held the positions of secretary and treasurer at Curis from March 2016 to
March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial
Officer of Dicerna Pharmaceuticals, Inc., a biotechnology company, from December
2013 to December 2015. Prior to such role, he was the Chief Financial Officer of
Valeritas, Inc., a medical technology company, from March 2010 to December 2013.
Before joining Valeritas, Inc., he was the Chief Financial Officer of Amicus
Therapeutics, Inc., a biotechnology company, from October 2006 to October 2009.
In prior positions, he spent six years as Corporate Controller of Biogen Inc., a
biotechnology company, and six years in various senior financial roles at E.I.
du Pont de Nemours and Company, a chemical, petroleum and biotechnology company,
in the U.S. and Asia. Mr. Dentzer holds a B.A. in philosophy from Boston College
and an M.B.A. from the University of Chicago.
Mr. Dentzer's Class II term will expire at the Company's Annual Meeting of
Stockholders in 2024. Mr. Dentzer will receive standard non-employee director
fees, including an initial grant of stock options under the Company's 2018 Stock
Incentive Plan, as amended (the "Plan"), to purchase 2,667 shares of the
Company's common stock, vesting in three equal installments with the first
vesting date on January 1, 2023, and annually thereafter.
The Board has determined that Mr. Dentzer is an independent director in
accordance with the applicable rules of the SEC and The NASDAQ Stock Market. Mr.
Dentzer does not have any relationship with the Company that would require
disclosure pursuant to Item 404(a) of SEC Regulation S-K.
On October 3, 2022, the Company issued a press release announcing the
appointment of Mr. Dentzer, a copy of which is attached hereto as Exhibit 99.1
to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated October 3, 2022, announcing appointment of James
E. Dentzer
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses